ImmuCell Corp (ICCC) Q2 2024 Filing Summary
Business Context and Reporting Period
This summary covers the Unaudited Quarterly Report on Form 10-Q for ImmuCell Corporation for the period ended June 30, 2024. ImmuCell is an animal health company focused on dairy and beef cattle, primarily through its First Defense product line (preventing scours in calves) and the development of Re-Tain (a treatment for subclinical mastitis). The company operates two reportable segments: Scours and Mastitis.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Product Sales | $5.47 million | $3.53 million | $12.73 million | $6.98 million |
| Gross Margin | $1.23 million (22%) | $1.04 million (30%) | $3.53 million (28%) | $1.34 million (19%) |
| Net Operating Loss | $(1.39) million | $(1.30) million | $(1.69) million | $(3.56) million |
| Net Loss | $(1.53) million | $(1.38) million | $(1.97) million | $(3.69) million |
| Net Loss Per Share (Basic/Diluted) | $(0.20) | $(0.18) | $(0.25) | $(0.48) |
| Cash and Equivalents | $1.32 million (as of June 30, 2024) | |||
| Total Debt (Current + Long-Term) | $11.26 million (as of June 30, 2024) | |||
| Operating Cash Flow (YTD) | $1.00 million | $(3.44) million |
Material Changes vs. Prior Period
- Revenue Growth: Product sales increased 55% in Q2 2024 compared to Q2 2023, driven by higher selling prices and improved product supply following production remediation efforts.
- Margin Compression: Gross margin percentage decreased to 22% in Q2 2024 from 30% in Q2 2023. This decline is attributed to inventory write-offs due to production contamination events ($316,000 cost of scrap in Q2 2024) and higher fixed costs per unit during ramp-up.
- Improved Cash Flow: Operating cash flow swung from a use of $3.44 million in the first half of 2023 to a generation of $1.00 million in the first half of 2024. This improvement was driven by a reduction in net loss and a decrease in inventory levels ($512,000 reduction).
- Debt Service: Interest expense increased to $142,000 in Q2 2024 from $89,000 in Q2 2023 due to new debt facilities secured in late 2023.
Guidance, Outlook, and Risks
- Production & Contamination: The company experienced a fourth contamination event in early 2024 impacting work-in-process inventory. Remediation steps implemented in late April 2024 appear successful, with no contamination reported since. Management aims to reach an annual production capacity of ~$30 million for the First Defense line.
- Re-Tain Development: The company is awaiting FDA approval for Re-Tain. A fourth submission of the Chemistry, Manufacturing, and Controls (CMC) Technical Section is pending, contingent on clearing inspectional observations at the contract manufacturer's facility. A controlled market launch is planned upon approval.
- Liquidity: Management believes current cash and anticipated gross margins are sufficient to fund operations for at least 12 months. An At-The-Market (ATM) offering agreement was utilized in Q2, raising net proceeds of approximately $253,000.
- Debt Covenants: The company has a minimum Debt Service Coverage (DSC) ratio requirement of 1.35. Lenders have preemptively waived this covenant for the periods ending June 30, 2024, and September 30, 2024. The company must meet the ratio for the year ending December 31, 2024.
- Customer Concentration: Two distributors accounted for approximately 79% of sales and 77% of accounts receivable as of June 30, 2024.
Investor Verification Checklist
- Contamination Remediation: Verify the sustainability of the "no contamination" run rate post-April 2024 and the impact of future scrap on gross margins.
- Debt Covenant Compliance: Monitor the company's ability to meet the 1.35 DSC ratio for the full year 2024, given the waiver history.
- Re-Tain Regulatory Timeline: Track the status of the FDA inspectional observations at the contract manufacturer's facility, which is the critical path for the fourth CMC submission.
- Inventory Levels: Assess the balance between maintaining sufficient raw material (colostrum) inventory and the risk of obsolescence or further write-downs.
- ATM Offering Activity: Monitor future equity dilution via the ATM agreement as a primary source of liquidity.